Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other brokerages also recently commented on FGEN. Mizuho reissued a “buy” rating and set a $65.00 price objective on shares of FibroGen in a research report on Monday, August 26th. BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. TheStreet raised FibroGen from a “d+” rating to a “c” rating in a research report on Tuesday, August 13th. Finally, Zacks Investment Research raised FibroGen from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a research report on Tuesday, August 13th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $57.17.
Shares of FibroGen stock traded up $3.65 on Friday, reaching $41.62. 4,519,800 shares of the company were exchanged, compared to its average volume of 705,728. FibroGen has a 1-year low of $33.51 and a 1-year high of $61.23. The company has a market cap of $3.47 billion, a P/E ratio of -40.41 and a beta of 1.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.73 and a quick ratio of 9.71. The stock’s 50 day moving average price is $38.54 and its 200-day moving average price is $41.93.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $1.75. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The business had revenue of $191.57 million during the quarter, compared to the consensus estimate of $29.03 million. During the same period in the previous year, the company posted ($0.28) earnings per share. The business’s revenue for the quarter was up 335.9% on a year-over-year basis. On average, research analysts predict that FibroGen will post -0.37 earnings per share for the current fiscal year.
In related news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the completion of the sale, the chief executive officer now owns 2,356,578 shares in the company, valued at $104,467,102.74. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $38.27, for a total value of $229,620.00. Following the sale, the director now owns 34,400 shares of the company’s stock, valued at approximately $1,316,488. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,156 shares of company stock valued at $4,484,043. 8.96% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Captrust Financial Advisors purchased a new stake in FibroGen during the second quarter worth approximately $90,000. US Bancorp DE lifted its stake in FibroGen by 79.7% during the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 963 shares during the last quarter. Usca Ria LLC purchased a new stake in FibroGen during the third quarter worth approximately $123,000. Convergence Investment Partners LLC purchased a new stake in FibroGen during the third quarter worth approximately $137,000. Finally, Nisa Investment Advisors LLC lifted its stake in FibroGen by 729.8% during the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 3,430 shares during the last quarter. Hedge funds and other institutional investors own 69.87% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: Penny Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.